Article

Comparable Immune Escape Capacity Between KP.2 and Other SARS-CoV-2 Variants in the Central Chinese Population After the First COVID-19 Booster

2025-01-22

Abstract excerpt

The neutralisation ability of homologous and heterologous booster vaccinations against the KP.2 variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is unknown. We evaluated Omicron variants (XBB.1, JN.1, and KP.2) neutralisation in participants vaccinated with heterologous versus homologous boosters. In 38 participants each from homologous and heter-ologous booster groups over 690 days, serum p...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 248b8090-2892-5322-8ef4-5132c2acad87
DOI: 10.20944/preprints202501.1560.v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Comparable Immune Escape Capacity Between KP.2 and Other SARS-CoV-2 Variants in the Central Chinese Population After the First COVID-19 BoosterDOI 10.20944/preprints202501.1560.v1Read

Recombinant XBB.1.5 boosters induce robust neutralization against KP.2- and KP.3-included JN.1 sublineagesSemantic proximity Read

Antibody neutralization to SARS-CoV-2 and variants after one year in WuhanSemantic proximity Read

Antibody responses to SARS-CoV-2 variants LP.8.1, LF.7.1, NB.1.8.1, XFG and BA.3.2 following KP.2 monovalent mRNA vaccinationSemantic proximity Read

Evaluation of the cross reactivity of neutralising antibody response in vaccinated human and convalescent hamster sera against SARS-CoV-2 variants up to and including JN.1 using an authentic virus neutralisation assaySemantic proximity Read

Sub-optimal Neutralisation of Omicron (B.1.1.529) Variant by Antibodies induced by Vaccine alone or SARS-CoV-2 Infection plus Vaccine (Hybrid Immunity) post 6-monthsSemantic proximity Read

Three-dose vaccination-induced immune responses protect against SARS-CoV-2 Omicron BA.2Semantic proximity Read

Efficacy of Heterologous Boosting Using Recombinant SARS-CoV-2 Fusion Protein Vaccine: A Randomized, Double-Blind and Placebo-Controlled Phase III TrialSemantic proximity Read

From Wuhan to Omicron K.P2 strain: A comprehensive review of SARS-CoV-2 phylogeny and public health implications of the latest booster vaccine.Semantic proximity Read

Three-Dose Vaccination-Induced Immune Responses Protect Against SARS-CoV-2 Omicron BA.2Semantic proximity Read

A survey and antibody test following the surge of SARS-CoV-2 Omicron infection in ChinaSemantic proximity Read

Impact of LP.8.1-Adapted mRNA Vaccination on SARS-CoV-2 Variant NeutralisationSemantic proximity Read